For its part, Teva has been aggressively expanding its global leadership in generics, in part through acquisitions. Two years ago it acquired Barr Pharmaceuticals, an American company, for about $7.5 billion. And Teva has indicated that ...
FRANKFURT — Israeli drug maker Teva has beaten out rivals Pfizer and Actavis to acquire German generic drug maker Ratiopharm GmbH — in a deal announced Thursday worth some €3.6 billion, or nearly $5 billion. ...
For its part, Teva has been aggressively expanding its global leadership in generics, in part through acquisitions. Two years ago it acquired Barr Pharmaceuticals, an American company, for about $7.5 billion. And Teva has indicated that ...
For its part, Teva has been aggressively expanding its global leadership in generics, in part through acquisitions. Two years ago it acquired Barr Pharmaceuticals, an American company, for about $7.5 billion. And Teva has indicated that ...
Teva Pharmaceutical Industries has won the bidding contest for German generic drug maker Ratiopharm, beating out Pfizer and Actavis, three people close to the matter told Reuters.
No comments:
Post a Comment